Abstract P4-08-04: The clinical utility of oncotype Dx for patients with recurrence scores of 10 or less: A value based pathology study of tumor histopathology and outcomes analysis in an integrated delivery and finance health system

MLA

Rohit Bhargava, et al. “Abstract P4-08-04: The Clinical Utility of Oncotype Dx for Patients with Recurrence Scores of 10 or Less: A Value Based Pathology Study of Tumor Histopathology and Outcomes Analysis in an Integrated Delivery and Finance Health System.” Cancer Research, vol. 78, Feb. 2018, pp. P4-08. EBSCOhost, https://doi.org/10.1158/1538-7445.sabcs17-p4-08-04.

APA

Rohit Bhargava, S Smalley, A Onisko, David J. Dabbs, K Serdy, Adam Brufsky, Beth Z. Clark, & S Perkins. (2018). Abstract P4-08-04: The clinical utility of oncotype Dx for patients with recurrence scores of 10 or less: A value based pathology study of tumor histopathology and outcomes analysis in an integrated delivery and finance health system. Cancer Research, 78, P4-08. https://doi.org/10.1158/1538-7445.sabcs17-p4-08-04

Chicago

Rohit Bhargava, S Smalley, A Onisko, David J. Dabbs, K Serdy, Adam Brufsky, Beth Z. Clark, and S Perkins. 2018. “Abstract P4-08-04: The Clinical Utility of Oncotype Dx for Patients with Recurrence Scores of 10 or Less: A Value Based Pathology Study of Tumor Histopathology and Outcomes Analysis in an Integrated Delivery and Finance Health System.” Cancer Research 78 (February): P4-08. doi:10.1158/1538-7445.sabcs17-p4-08-04.